Across TCGA pan-cancer cohorts, RNA5S17 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated RNA5S17 data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNA5S17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNA5S17 expression acts as an unfavorable survival marker.
STAD are the cancer types where RNA5S17 RNA most reproducibly stratifies survival.